Cargando…

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ranzani, Otavio T., Hitchings, Matt D. T., de Melo, Rosana Leite, de França, Giovanny V. A., Fernandes, Cássia de Fátima R., Lind, Margaret L., Torres, Mario Sergio Scaramuzzini, Tsuha, Daniel Henrique, David, Leticia C. S., Said, Rodrigo F. C., Almiron, Maria, de Oliveira, Roberto D., Cummings, Derek A. T., Dean, Natalie E., Andrews, Jason R., Ko, Albert I., Croda, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537178/ https://www.ncbi.nlm.nih.gov/pubmed/36202800 http://dx.doi.org/10.1038/s41467-022-33169-0

Ejemplares similares

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
por: Accorsi, Emma K., et al.
Publicado: (2022)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study
por: Hitchings, Matt D.T., et al.
Publicado: (2021)

Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study
por: Hitchings, Matt D T, et al.
Publicado: (2022)

Homologous and Heterologous Covid-19 Booster Vaccinations
por: Atmar, Robert L., et al.
Publicado: (2022)

Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
por: Lind, Margaret L., et al.
Publicado: (2022)

Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
por: Hitchings, Matt D. T., et al.
Publicado: (2021)

Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
por: Ranzani, Otavio T, et al.
Publicado: (2021)

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans
por: Mayr, Florian B., et al.
Publicado: (2022)

AEs after homologous versus heterologous COVID-19 booster
Publicado: (2022)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
por: Hitchings, Matt D.T., et al.
Publicado: (2021)

Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients
por: Gaete-Argel, Aracelly, et al.
Publicado: (2023)

Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile
por: Acevedo, Johanna, et al.
Publicado: (2023)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023)

Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron
por: Bottero, Daniela, et al.
Publicado: (2023)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
por: Fang, Zhenhao, et al.
Publicado: (2022)

Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine
por: Rzymski, Piotr, et al.
Publicado: (2022)

Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
por: Honfi, Dániel, et al.
Publicado: (2022)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster vaccination
por: Vadrevu, Krishna Mohan
Publicado: (2023)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
por: Li, Gen, et al.
Publicado: (2022)

Investigation of Adverse Events Experienced by Healthcare Workers following Immunization with Homologous or Heterologous COVID-19 Booster Vaccinations
por: Wei, Yunhua, et al.
Publicado: (2022)

Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster – authors' reply
por: Rose, Winsley, et al.
Publicado: (2023)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
por: Zhang, Lei, et al.
Publicado: (2023)

Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant
por: Zuo, Fanglei, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations
por: Trombetta, Claudia Maria, et al.
Publicado: (2022)

Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster
por: Peng, Pai, et al.
Publicado: (2022)

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
por: Tay, Matthew Zirui, et al.
Publicado: (2023)

A Cross-Sectional Study of Untoward Reactions Following Homologous and Heterologous COVID-19 Booster Immunizations in Recipients Seventeen Years of Age and Older
por: Tamburro, Manuela, et al.
Publicado: (2022)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
por: Assawakosri, Suvichada, et al.
Publicado: (2022)

Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
por: Cerqueira-Silva, Thiago, et al.
Publicado: (2022)

Comparing the SARS-CoV-2-specific antibody response in human milk after homologous and heterologous booster vaccinations
por: Mulleners, Sien J., et al.
Publicado: (2023)

Safety Profile of Homologous and Heterologous Booster COVID-19 Vaccines in Physicians in Quito-Ecuador: A Cross-Sectional Study
por: Flores-Lastra, Nancy, et al.
Publicado: (2023)

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
por: Pérez-Then, Eddy, et al.
Publicado: (2022)

Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel
por: Park, Sungsoo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qvv4fg89l0jdtpjhqagmt3dgq5